Keywords
Last Name
Institution

Joseph Friedman

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentPsychiatry
Address
    Other Positions
    TitleASSOCIATE PROFESSOR
    InstitutionMount Sinai
    DepartmentNeuroscience


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Friedman JH, Abrantes AM. The Glabellar reflex is a poor measure of Parkinson motor severity. Int J Neurosci. 2013 Jun; 123(6):417-9.
      View in: PubMed
    2. Friedman JH. Past exposure to neuroleptics is associated with the risk of developing Parkinson's disease. Evid Based Ment Health. 2013 Feb; 16(1):27.
      View in: PubMed
    3. Tang CY, Narula J, Friedman JI. Novel imaging strategies for assessment of cerebrovascular involvement. Mt Sinai J Med. 2012 Nov-Dec; 79(6):674-82.
      View in: PubMed
    4. Abrantes AM, Friedman JH, Brown RA, Strong DR, Desaulniers J, Ing E, Saritelli J, Riebe D. Physical activity and neuropsychiatric symptoms of Parkinson disease. J Geriatr Psychiatry Neurol. 2012 Sep; 25(3):138-45.
      View in: PubMed
    5. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang M-, Rosado L, Orbe Reilly M, Ruiz D, Ross B, Verbitsky M, Kisselev S, Louis E, Comella C, Colcher A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Payami H, Molho E, Factor S, Ottman R, Clark LN, Marder K. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012 May 1; 78(18):1434-40.
      View in: PubMed
    6. Srivastava A, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Caccappolo E, Comella C, Colcher A, Siderowf A, Jennings D, Nance M, Bressman S, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Alcalay RN, Ross B, Orbe Reilly M, Rezak M, Novak K, Friedman JH, Pfeiffer RD, Marsh L, Hiner B, Merle D, Ottman R, Clark LN, Marder K. The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord. 2011 Dec; 17(10):740-4.
      View in: PubMed
    7. Friedman JH. Atypical antipsychotic drugs in the treatment of Parkinson's disease. J Pharm Pract. 2011 Dec; 24(6):534-40.
      View in: PubMed
    8. Friedman JH, Agarwal P, Alcalay R, Black KJ, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Int J Neurosci. 2011 Aug; 121(8):472-6.
      View in: PubMed
    9. Tang CY, Friedman JI, Carpenter DM, Novakovic V, Eaves E, Ng J, Wu YW, Gottlieb S, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, McGinn TG, Flanagan L, Davis KL. The effects of hypertension and body mass index on diffusion tensor imaging in schizophrenia. Schizophr Res. 2011 Aug; 130(1-3):94-100.
      View in: PubMed
    10. Schneiderman JS, Hazlett EA, Chu KW, Zhang J, Goodman CR, Newmark RE, Torosjan Y, Canfield EL, Entis J, Mitropoulou V, Tang CY, Friedman J, Buchsbaum MS. Brodmann area analysis of white matter anisotropy and age in schizophrenia. Schizophr Res. 2011 Aug; 130(1-3):57-67.
      View in: PubMed
    11. Friedman JI, Lindenmayer JP, Alcantara F, Bowler S, Parak M, White L, Iskander A, Parrella M, Adler DN, Tsopelas ND, Tsai WY, Novakovic V, Novakovick V, Harvey PD, Davis KL, Kaushik S. Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology. 2011 May; 36(6):1289-95.
      View in: PubMed
    12. Friedman JH. Managing idiopathic Parkinson's disease in patients with schizophrenic disorders. Parkinsonism Relat Disord. 2011 Mar; 17(3):198-200.
      View in: PubMed
    13. Caccappolo E, Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Cote LJ, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Siderowf AD, Ross BM, Verbitsky M, Kisselev S, Ottman R, Clark LN, Marder KS. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc. 2011 Jan; 17(1):91-100.
      View in: PubMed
    14. Lo AC, Chang VC, Gianfrancesco MA, Friedman JH, Patterson TS, Benedicto DF. Reduction of freezing of gait in Parkinson's disease by repetitive robot-assisted treadmill training: a pilot study. J Neuroeng Rehabil. 2010; 7:51.
      View in: PubMed
    15. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Ross BM, Verbitsky M, Kisselev S, Louis ED, Comella C, Colcher A, Jennings D, Nance MA, Bressman SB, Scott WK, Tanner C, Mickel S, Andrews H, Waters C, Fahn S, Cote L, Frucht S, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Marder K, Clark LN. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep; 67(9):1116-22.
      View in: PubMed
    16. Friedman JI, Wallenstein S, Moshier E, Parrella M, White L, Bowler S, Gottlieb S, Harvey PD, McGinn TG, Flanagan L, Davis KL. The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry. 2010 Oct; 167(10):1232-9.
      View in: PubMed
    17. Friedman JH. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord. 2010 Nov; 16(9):553-60.
      View in: PubMed
    18. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol. 2010 Jun; 67(6):731-8.
      View in: PubMed
    19. Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):805-22.
      View in: PubMed
    20. Friedman JH. Recommendations on the drug treatment of psychosis in Parkinson's disease. Am J Med. 2010 Apr; 123(4):e19; author reply e21.
      View in: PubMed
    21. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010 Aug; 32(7):775-9.
      View in: PubMed
    22. Thomas AA, Rogers JM, Amick MM, Friedman JH. Falls and the falls efficacy scale in Parkinson's disease. J Neurol. 2010 Jul; 257(7):1124-8.
      View in: PubMed
    23. Segal D, Haznedar MM, Hazlett EA, Entis JJ, Newmark RE, Torosjan Y, Schneiderman JS, Friedman J, Chu KW, Tang CY, Buchsbaum MS, Hof PR. Diffusion tensor anisotropy in the cingulate gyrus in schizophrenia. Neuroimage. 2010 Apr 1; 50(2):357-65.
      View in: PubMed
    24. Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010 Jan-Feb; 33(1):5-10.
      View in: PubMed
    25. Thomas AA, Friedman JH. Current use of clozapine in Parkinson disease and related disorders. Clin Neuropharmacol. 2010 Jan-Feb; 33(1):14-6.
      View in: PubMed
    26. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1517-22.
      View in: PubMed
    27. Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, Friedman JH. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology. 2010 Mar; 35(4):881-92.
      View in: PubMed
    28. Friedman JH. Medication trials in an imperfect world: gout and Parkinson's disease. Med Health R I. 2009 Nov; 92(11):350.
      View in: PubMed
    29. Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. Mov Disord. 2009 Oct 15; 24(13):1941-8.
      View in: PubMed
    30. Cramer CK, Friedman JH, Amick MM. Olfaction and apathy in Parkinson's disease. Parkinsonism Relat Disord. 2010 Feb; 16(2):124-6.
      View in: PubMed
    31. Friedman J, Platnick J, Farruggia S, Khilko N, Mody K, Tyshkov M. Ménétrier disease. Radiographics. 2009 Jan-Feb; 29(1):297-301.
      View in: PubMed
    32. Grace J, Amick MM, Friedman JH. A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009 Jan; 80(1):18-23.
      View in: PubMed
    33. Carpenter DM, Tang CY, Friedman JI, Hof PR, Stewart DG, Buchsbaum MS, Harvey PD, Gorman JG, Davis KL. Temporal characteristics of tract-specific anisotropy abnormalities in schizophrenia. Neuroreport. 2008 Sep 17; 19(14):1369-72.
      View in: PubMed
    34. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008 Aug 12; 71(7):481-5.
      View in: PubMed
    35. Friedman JI, Tang C, Carpenter D, Buchsbaum M, Schmeidler J, Flanagan L, Golembo S, Kanellopoulou I, Ng J, Hof PR, Harvey PD, Tsopelas ND, Stewart D, Davis KL. Diffusion tensor imaging findings in first-episode and chronic schizophrenia patients. Am J Psychiatry. 2008 Aug; 165(8):1024-32.
      View in: PubMed
    36. Friedman JH. Introduction to geriatric neurology issue. Med Health R I. 2008 May; 91(5):126.
      View in: PubMed
    37. Friedman JH. Gait in the elderly. Med Health R I. 2008 May; 91(5):134-5.
      View in: PubMed
    38. Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord. 2008 Mar 15; 23(4):484-500.
      View in: PubMed
    39. Friedman JH, Millman RP. Sleep disturbances and Parkinson's disease. CNS Spectr. 2008 Mar; 13(3 Suppl 4):12-7.
      View in: PubMed
    40. Friedman JH, Amick MM, Chou KL. Rhinorrhea and olfaction in Parkinson disease. Neurology. 2008 Feb 5; 70(6):487-9.
      View in: PubMed
    41. Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, Parrella M, Bowler S, Elbaz Z, Flanagan L, Harvey PD. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol. 2008 Feb; 28(1):59-63.
      View in: PubMed
    42. França MC, D'Abreu A, Friedman JH, Nucci A, Lopes-Cendes I. Chronic pain in Machado-Joseph disease: a frequent and disabling symptom. Arch Neurol. 2007 Dec; 64(12):1767-70.
      View in: PubMed
    43. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K. Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry. 2007 Dec 15; 62(12):1396-404.
      View in: PubMed
    44. Friedman JI, Vrijenhoek T, Markx S, Janssen IM, van der Vliet WA, Faas BH, Knoers NV, Cahn W, Kahn RS, Edelmann L, Davis KL, Silverman JM, Brunner HG, van Kessel AG, Wijmenga C, Ophoff RA, Veltman JA. CNTNAP2 gene dosage variation is associated with schizophrenia and epilepsy. Mol Psychiatry. 2008 Mar; 13(3):261-6.
      View in: PubMed
    45. Tang CY, Friedman J, Shungu D, Chang L, Ernst T, Stewart D, Hajianpour A, Carpenter D, Ng J, Mao X, Hof PR, Buchsbaum MS, Davis K, Gorman JM. Correlations between Diffusion Tensor Imaging (DTI) and Magnetic Resonance Spectroscopy (1H MRS) in schizophrenic patients and normal controls. BMC Psychiatry. 2007; 7:25.
      View in: PubMed
    46. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007 Jun 15; 22(8):1061-8.
      View in: PubMed
    47. Friedman JH. "... But I can still sue you, can't I"? Med Health R I. 2007 Jun; 90(6):170.
      View in: PubMed
    48. Liperoti R, Onder G, Lapane KL, Mor V, Friedman JH, Bernabei R, Gambassi G. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry. 2007 Jun; 68(6):929-34.
      View in: PubMed
    49. Chou KL, Borek LL, Friedman JH. The management of psychosis in movement disorder patients. Expert Opin Pharmacother. 2007 May; 8(7):935-43.
      View in: PubMed
    50. Borek LL, Kohn R, Friedman JH. Phenomenology of dreams in Parkinson's disease. Mov Disord. 2007 Jan 15; 22(2):198-202.
      View in: PubMed
    51. Chou KL, Friedman JH. Treatment-induced mental changes in Parkinson's disease. Handb Clin Neurol. 2007; 84:219-40.
      View in: PubMed
    52. Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006 Dec; 21(12):2078-81.
      View in: PubMed
    53. Grace J, Mendelsohn A, Friedman JH. A comparison of fatigue measures in Parkinson's disease. Parkinsonism Relat Disord. 2007 Oct; 13(7):443-5.
      View in: PubMed
    54. Friedman JH. Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning. Neurology. 2006 Aug 22; 67(4):564-6.
      View in: PubMed
    55. Buchsbaum MS, Friedman J, Buchsbaum BR, Chu KW, Hazlett EA, Newmark R, Schneiderman JS, Torosjan Y, Tang C, Hof PR, Stewart D, Davis KL, Gorman J. Diffusion tensor imaging in schizophrenia. Biol Psychiatry. 2006 Dec 1; 60(11):1181-7.
      View in: PubMed
    56. Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson's disease. CNS Spectr. 2006 Jul; 11(7):541-54.
      View in: PubMed
    57. Borek LL, Kohn R, Friedman JH. Mood and sleep in Parkinson's disease. J Clin Psychiatry. 2006 Jun; 67(6):958-63.
      View in: PubMed
    58. Friedman JH. Anticholinergics in dementia and other confounding problems. Am J Geriatr Psychiatry. 2006 Apr; 14(4):384; author reply 384-5.
      View in: PubMed
    59. Friedman JH. Atypical antipsychotics have very different adverse effect profiles and should not be lumped together. Arch Intern Med. 2006 Mar 13; 166(5):586; author reply 586-7.
      View in: PubMed
    60. Chou KL, Friedman JH. Are atypical antipsychotics associated with a reduced risk of developing parkinsonism? Nat Clin Pract Neurol. 2006 Mar; 2(3):132-3.
      View in: PubMed
    61. Hochstadt J, Nakano H, Lieberman P, Friedman J. The roles of sequencing and verbal working memory in sentence comprehension deficits in Parkinson's disease. Brain Lang. 2006 Jun; 97(3):243-57.
      View in: PubMed
    62. Rieckmann N, Reichenberg A, Bowie CR, Parrella M, White L, Friedman JI, Harvey PD. Depressed mood and its functional correlates in institutionalized schizophrenia patients. Schizophr Res. 2005 Sep 15; 77(2-3):179-87.
      View in: PubMed
    63. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol. 2005 Sep-Oct; 28(5):215-9.
      View in: PubMed
    64. Friedman JI, Ocampo R, Elbaz Z, Parrella M, White L, Bowler S, Davis KL, Harvey PD. The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia. J Clin Psychopharmacol. 2005 Jun; 25(3):237-42.
      View in: PubMed
    65. Friedman J, Khoury H, Adkins D, Devine S, Nervi B, Edwards T, Dipersio J, Vij R. Pilot study of 13cis-retinoic acid+dexamethasone+alpha interferon as maintenance therapy following high-dose chemotherapy and autologous stem cell transplant for multiple myeloma. Bone Marrow Transplant. 2005 May; 35(10):979-84.
      View in: PubMed
    66. Bowie CR, Tsapelas I, Friedman J, Parrella M, White L, Harvey PD. The longitudinal course of thought disorder in geriatric patients with chronic schizophrenia. Am J Psychiatry. 2005 Apr; 162(4):793-5.
      View in: PubMed
    67. Stein DL, Haramati LB, Spindola-Franco H, Friedman J, Klapper PJ. Intrathoracic lymphadenopathy in hospitalized patients with pneumococcal pneumonia. Chest. 2005 Apr; 127(4):1271-5.
      View in: PubMed
    68. White L, Opler LA, Harvey PD, Parrella M, Friedman JI. Activation symptoms and discharge in elderly chronic schizophrenic inpatients. J Nerv Ment Dis. 2004 Dec; 192(12):880-3.
      View in: PubMed
    69. Fernandez HH, Friedman JH, Lansang MC, Factor SA, Molho ES, Coskun DJ. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Parkinsonism Relat Disord. 2004 Oct; 10(7):439-41.
      View in: PubMed
    70. Friedman JH. Randomized, double-blind, placebo-controlled trials: the gold standard? Med Health R I. 2004 Sep; 87(9):262-3.
      View in: PubMed
    71. Ready RE, Friedman J, Grace J, Fernandez H. Testosterone deficiency and apathy in Parkinson's disease: a pilot study. J Neurol Neurosurg Psychiatry. 2004 Sep; 75(9):1323-6.
      View in: PubMed
    72. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord. 2004 Aug; 19(8):916-23.
      View in: PubMed
    73. Al-Yacoub M, Friedman JH, Fernandez HH. Hemiballismus from a parietal stroke in a Parkinson patient. Mov Disord. 2004 Aug; 19(8):986-8.
      View in: PubMed
    74. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord. 2004 Jul; 19(7):831-3.
      View in: PubMed
    75. Fernandez HH, Lannon MC, Trieschmann ME, Friedman JH. Botulinum toxin type B for gait freezing in Parkinson's disease. Med Sci Monit. 2004 Jul; 10(7):CR282-4.
      View in: PubMed
    76. Friedman JI, Stewart DG, Gorman JM. Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr. 2004 May; 9(5):350-5.
      View in: PubMed
    77. McGurk SR, Coleman T, Harvey PD, Reichenberg A, White L, Friedman J, Parrella M, Davis KL. Working memory performance in poor outcome schizophrenia: relationship to age and executive functioning. J Clin Exp Neuropsychol. 2004 Apr; 26(2):153-60.
      View in: PubMed
    78. Friedman JH, Fernandez HH, Trieschmann MM. Parkinsonism in a nursing home: underrecognition. J Geriatr Psychiatry Neurol. 2004 Mar; 17(1):39-41.
      View in: PubMed
    79. Friedman JI. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl). 2004 Jun; 174(1):45-53.
      View in: PubMed
    80. Friedman JH. Historical perspective on movement disorders. J Clin Psychiatry. 2004; 65 Suppl 9:3-8.
      View in: PubMed
    81. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol. 2004 Jan-Feb; 27(1):4-5.
      View in: PubMed
    82. Friedman JH. Gratification. Med Health R I. 2003 Dec; 86(12):374.
      View in: PubMed
    83. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
      View in: PubMed
    84. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord. 2003 May; 18(5):510-4.
      View in: PubMed
    85. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry. 2003 May; 60(5):443-56.
      View in: PubMed
    86. Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology. 2003 Apr 8; 60(7):1119-24.
      View in: PubMed
    87. Friedman JH. Re: Atypical antipsychotics mechanisms of action. Can J Psychiatry. 2003 Feb; 48(1):62; author reply 62-4.
      View in: PubMed
    88. Friedman JH. Re: Klintenberg et al, tardive dyskinesia model in the common marmoset. Mov Disord. 2003 Jan; 18(1):114-5.
      View in: PubMed
    89. Friedman JH. Presumed rapid eye movement behavior disorder in Machado-Joseph disease (spinocerebellar ataxia type 3). Mov Disord. 2002 Nov; 17(6):1350-3.
      View in: PubMed
    90. Zawacki TM, Grace J, Friedman JH, Sudarsky L. Executive and emotional dysfunction in Machado-Joseph disease. Mov Disord. 2002 Sep; 17(5):1004-10.
      View in: PubMed
    91. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry. 2002 Sep 1; 52(5):438-45.
      View in: PubMed
    92. Friedman JI, Harvey PD, McGurk SR, White L, Parrella M, Raykov T, Coleman T, Adler DN, Davis KL. Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity. Am J Psychiatry. 2002 Aug; 159(8):1388-94.
      View in: PubMed
    93. Cahn-Weiner DA, Grace J, Ott BR, Fernandez HH, Friedman JH. Cognitive and behavioral features discriminate between Alzheimer's and Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol. 2002 Jun; 15(2):79-87.
      View in: PubMed
    94. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry. 2002 Jun; 63(6):513-5.
      View in: PubMed
    95. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, White L, Parrella M, Davis KL. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002 Mar 1; 51(5):349-57.
      View in: PubMed
    96. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov Disord. 2002 Jan; 17(1):221-2.
      View in: PubMed
    97. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson-sensitive populations. J Geriatr Psychiatry Neurol. 2002; 15(3):156-70.
      View in: PubMed
    98. Fernandez HH, Tabamo RE, David RR, Friedman JH. Predictors of depressive symptoms among spouse caregivers in Parkinson's disease. Mov Disord. 2001 Nov; 16(6):1123-5.
      View in: PubMed
    99. Friedman JH, Friedman H. Fatigue in Parkinson's disease: a nine-year follow-up. Mov Disord. 2001 Nov; 16(6):1120-2.
      View in: PubMed
    100. Harvey PD, Bowie CR, Friedman JI. Cognition in schizophrenia. Curr Psychiatry Rep. 2001 Oct; 3(5):423-8.
      View in: PubMed
    101. Friedman JI, Harvey PD, Coleman T, Moriarty PJ, Bowie C, Parrella M, White L, Adler D, Davis KL. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am J Psychiatry. 2001 Sep; 158(9):1441-8.
      View in: PubMed
    102. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, Parrella M, Davis KL. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology. 2001 Sep; 25(3):402-9.
      View in: PubMed
    103. Harvey PD, Serper MR, White L, Parrella MJ, McGurk SR, Moriarty PJ, Bowie C, Vadhan N, Friedman J, Davis KL. The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr Psychiatry. 2001 Jul-Aug; 42(4):306-13.
      View in: PubMed
    104. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8.
      View in: PubMed
    105. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001 Mar 27; 56(6):805-7.
      View in: PubMed
    106. Malaspina D, Goetz RR, Friedman JH, Kaufmann CA, Faraone SV, Tsuang M, Cloninger CR, Nurnberger JI, Blehar MC. Traumatic brain injury and schizophrenia in members of schizophrenia and bipolar disorder pedigrees. Am J Psychiatry. 2001 Mar; 158(3):440-6.
      View in: PubMed
    107. Friedman JH, Fernandez HH. Autopsy follow-up of a patient with schizophrenia and presumed idiopathic Parkinson's disease. Clin Neuropharmacol. 2001 Mar-Apr; 24(2):120-1.
      View in: PubMed
    108. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001 Jan; 16(1):135-9.
      View in: PubMed
    109. Malaspina D, Goetz RR, Yale S, Berman A, Friedman JH, Tremeau F, Printz D, Amador X, Johnson J, Brown A, Gorman JM. Relation of familial schizophrenia to negative symptoms but not to the deficit syndrome. Am J Psychiatry. 2000 Jun; 157(6):994-1003.
      View in: PubMed
    110. Harvey PD, Moriarty PJ, Friedman JI, White L, Parrella M, Mohs RC, Davis KL. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. Biol Psychiatry. 2000 Jun 1; 47(11):962-8.
      View in: PubMed
    111. Fernandez HH, Lapane KL, Ott BR, Friedman JH. Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. SAGE Study Group. Systematic Assessment and Geriatric drug use via Epidemiology. Mov Disord. 2000 May; 15(3):490-6.
      View in: PubMed
    112. Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000 May; 15(3):579-81.
      View in: PubMed
    113. Friedman JH. First annual April (fool's) commentary. Cognitive sinks: the black holes of neuropsychology: a brief overview. Med Health R I. 2000 Apr; 83(4):98-9.
      View in: PubMed
    114. Tabamo RE, Fernandez HH, Friedman JH, Lucas PR. Spinal surgery for severe scoliosis in Parkinson's disease. Med Health R I. 2000 Apr; 83(4):114-5.
      View in: PubMed
    115. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000 Mar; 15(2):201-11.
      View in: PubMed
    116. McGurk SR, Moriarty PJ, Harvey PD, Parrella M, White L, Friedman J, Davis KL. Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. J Neuropsychiatry Clin Neurosci. 2000; 12(2):257-64.
      View in: PubMed
    117. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord. 2000 Jan; 15(1):173-6.
      View in: PubMed
    118. Faraone SV, Meyer J, Matise T, Svrakic D, Pepple J, Malaspina D, Suarez B, Hampe C, Chan G, Aelony A, Friedman JH, Kaufmann C, Cloninger CR, Tsuang MT. Suggestive linkage of chromosome 10p to schizophrenia is not due to transmission ratio distortion. Am J Med Genet. 1999 Dec 15; 88(6):607-8.
      View in: PubMed
    119. Lapane KL, Fernandez HH, Friedman JH. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities. SAGE Study Group. Pharmacotherapy. 1999 Nov; 19(11):1321-7.
      View in: PubMed
    120. Friedman JI, Adler DN, Davis KL. The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease. Biol Psychiatry. 1999 Nov 1; 46(9):1243-52.
      View in: PubMed
    121. Friedman JI, Harvey PD, Kemether E, Byne W, Davis KL. Cognitive and functional changes with aging in schizophrenia. Biol Psychiatry. 1999 Oct 1; 46(7):921-8.
      View in: PubMed
    122. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 1999 May; 14(3):484-7.
      View in: PubMed
    123. Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol Psychiatry. 1999 Jan 1; 45(1):1-16.
      View in: PubMed
    124. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol. 1998 Sep-Oct; 21(5):285-8.
      View in: PubMed
    125. Friedman JH. Rapid onset tardive dyskinesia ("fly catcher tongue") in a neuroleptically naive patient induced by risperidone. Med Health R I. 1998 Aug; 81(8):271-2.
      View in: PubMed
    126. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, O'Brien CF, LeWitt PA, Koller WC. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord. 1998 May; 13(3):377-82.
      View in: PubMed
    127. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology. 1998 May; 50(5):1327-31.
      View in: PubMed
    128. Malaspina D, Friedman JH, Kaufmann C, Bruder G, Amador X, Strauss D, Clark S, Yale S, Lukens E, Thorning H, Goetz R, Gorman J. Psychobiological heterogeneity of familial and sporadic schizophrenia. Biol Psychiatry. 1998 Apr 1; 43(7):489-96.
      View in: PubMed
    129. Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1998 Apr; 50(4):1195-6.
      View in: PubMed
    130. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, Friedman J, Diamond GA. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998 Feb 17; 97(6):535-43.
      View in: PubMed
    131. Pickett ER, Kuniholm E, Protopapas A, Friedman J, Lieberman P. Selective speech motor, syntax and cognitive deficits associated with bilateral damage to the putamen and the head of the caudate nucleus: a case study. Neuropsychologia. 1998 Feb; 36(2):173-88.
      View in: PubMed
    132. Friedman JH, Ott BR. Should risperidone be used in Parkinson's disease? J Neuropsychiatry Clin Neurosci. 1998; 10(4):473-5.
      View in: PubMed
    133. Berman D, Germano G, Lewin H, Kang X, Kavanagh PB, Tapnio P, Harris M, Friedman J. Comparison of post-stress ejection fraction and relative left ventricular volumes by automatic analysis of gated myocardial perfusion single-photon emission computed tomography acquired in the supine and prone positions. J Nucl Cardiol. 1998 Jan-Feb; 5(1):40-7.
      View in: PubMed
    134. Herrera CR, Lewin A, Fiddes R, Friedman J, Linn W, Baker T, Balanoff D, Beach CL. Long-acting diltiazem CD is safe and effective in a hypertensive Mexican-American population. Pharmacotherapy. 1997 Nov-Dec; 17(6):1254-9.
      View in: PubMed
    135. Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry. 1997 Sep 15; 42(6):522-3.
      View in: PubMed
    136. Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology. 1997 Sep; 49(3):724-8.
      View in: PubMed
    137. Powchik P, Friedman J, Haroutunian V, Greenberg D, Altsteil L, Purohit D, Perl D, Davidson M. Apolipoprotein E4 in schizophrenia: a study of one hundred sixteen cases with concomitant neuropathological examination. Biol Psychiatry. 1997 Aug 15; 42(4):296-8.
      View in: PubMed
    138. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord. 1997 Jul; 12(4):483-96.
      View in: PubMed
    139. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology. 1997 Apr; 48(4):1077-81.
      View in: PubMed
    140. Benari B, Erel J, Allen HN, Friedman J, Kiat H, Silverman JM, Trento A, Berman D. Aneurysm of saphenous vein bypass graft detected by first-pass radionuclide ventriculography. Am Heart J. 1997 Jan; 133(1):133-6.
      View in: PubMed
    141. Amador XF, Friedman JH, Kasapis C, Yale SA, Flaum M, Gorman JM. Suicidal behavior in schizophrenia and its relationship to awareness of illness. Am J Psychiatry. 1996 Sep; 153(9):1185-8.
      View in: PubMed
    142. Mesko TW, Friedman J, Sendzischew H, Nixon DD. Rectal carcinoma metastatic to the thyroid gland. J Laryngol Otol. 1996 Feb; 110(2):192-5.
      View in: PubMed
    143. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry. 1995 Dec; 56(12):556-9.
      View in: PubMed
    144. Brown AS, Hembree WC, Friedman JH, Kaufmann CA, Gorman JM. The gonadal axis in men with schizophrenia. Psychiatry Res. 1995 Aug 28; 57(3):231-9.
      View in: PubMed
    145. Friedman JH. Punding on levodopa. Biol Psychiatry. 1994 Sep 1; 36(5):350-1.
      View in: PubMed
    146. Friedman JH. Clozapine treatment of psychosis in patients with tardive dystonia: report of three cases. Mov Disord. 1994 May; 9(3):321-4.
      View in: PubMed
    147. Van Train KF, Garcia EV, Maddahi J, Areeda J, Cooke CD, Kiat H, Silagan G, Folks R, Friedman J, Matzer L, et al. Multicenter trial validation for quantitative analysis of same-day rest-stress technetium-99m-sestamibi myocardial tomograms. J Nucl Med. 1994 Apr; 35(4):609-18.
      View in: PubMed
    148. Malaspina D, Wray AD, Friedman JH, Amador X, Yale S, Hasan A, Gorman JM, Kaufmann CA. Odor discrimination deficits in schizophrenia: association with eye movement dysfunction. J Neuropsychiatry Clin Neurosci. 1994; 6(3):273-8.
      View in: PubMed
    149. Malaspina D, Amador XF, Coleman EA, Mayr TL, Friedman JH, Sackeim HA. Smooth pursuit eye movement abnormality in severe major depression: effects of ECT and clinical recovery. J Neuropsychiatry Clin Neurosci. 1994; 6(1):36-42.
      View in: PubMed
    150. Friedman JH. Akathisia with clozapine. Biol Psychiatry. 1993 Jun 1-15; 33(11-12):852-3.
      View in: PubMed
    151. John ER, Easton P, Prichep LS, Friedman J. Standardized varimax descriptors of event related potentials: basic considerations. Brain Topogr. 1993; 6(2):143-62.
      View in: PubMed
    152. Lieberman P, Kako E, Friedman J, Tajchman G, Feldman LS, Jiminez EB. Speech production, syntax comprehension, and cognitive deficits in Parkinson's disease. Brain Lang. 1992 Aug; 43(2):169-89.
      View in: PubMed
    153. Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease? J Clin Psychiatry. 1992 Aug; 53(8):278-82.
      View in: PubMed
    154. Pannizzo F, Stallmeyer MJ, Friedman J, Jennis RJ, Zabriskie J, Plank C, Zimmerman R, Whalen JP, Cahill PT. Quantitative MRI studies for assessment of multiple sclerosis. Magn Reson Med. 1992 Mar; 24(1):90-9.
      View in: PubMed
    155. Johnson JA, Friedman J, Halligan RD, Birnbaumer M, Clark RB. Sensitization of adenylyl cyclase by P2 purinergic and M5 muscarinic receptor agonists in L cells. Mol Pharmacol. 1991 Oct; 40(4):539-46.
      View in: PubMed
    156. Lieberman P, Friedman J, Feldman LS. Syntax comprehension deficits in Parkinson's disease. J Nerv Ment Dis. 1990 Jun; 178(6):360-5.
      View in: PubMed
    157. Friedman JH, Ambler M. A case of senile chorea. Mov Disord. 1990; 5(3):251-3.
      View in: PubMed
    158. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord. 1990; 5(3):225-9.
      View in: PubMed
    159. Friedman JH, Lannon MC. Clozapine in the treatment of psychosis in Parkinson's disease. Neurology. 1989 Sep; 39(9):1219-21.
      View in: PubMed
    160. Friedman JH, Lannon MC. An open trial of controlled release carbidopa/L-dopa (sinemet CR) for the treatment of mild-to-moderate Parkinson's disease. Clin Neuropharmacol. 1989 Jun; 12(3):220-3.
      View in: PubMed
    161. Rozanski A, Bairey CN, Krantz DS, Friedman J, Resser KJ, Morell M, Hilton-Chalfen S, Hestrin L, Bietendorf J, Berman DS. Mental stress and the induction of silent myocardial ischemia in patients with coronary artery disease. N Engl J Med. 1988 Apr 21; 318(16):1005-12.
      View in: PubMed
    162. Friedman JH, Max J, Swift R. Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and L-dopa. Clin Neuropharmacol. 1987 Oct; 10(5):470-5.
      View in: PubMed
    163. Friedman JH, Wagner RL. Symptoms of neuroleptic malignant syndrome. Am J Psychiatry. 1987 Aug; 144(8):1105-6.
      View in: PubMed
    164. Anderson JL, Anastasiou-Nana MI, Heath BM, Menlove RL, Nanas JN, Friedman J. Efficacy of recainam, a new antiarrhythmic drug, for control of ventricular arrhythmias. Am J Cardiol. 1987 Aug 1; 60(4):281-7.
      View in: PubMed
    165. Friedman JH, Wagner RL. Akathisia: the syndrome of motor restlessness. Am Fam Physician. 1987 Feb; 35(2):145-9.
      View in: PubMed
    166. Friedman JH, Liu HM, Spremulli E, Calabresi P. Distant metastases from a malignant glioma: unusual complications associated with treatment of a glioblastoma: distant metastases and focal white matter degeneration. J Neurol Neurosurg Psychiatry. 1987 Feb; 50(2):237-8.
      View in: PubMed
    167. Kucharski LT, Wagner RL, Friedman JH. An investigation of the coexistence of abnormal involuntary movements, parkinsonism, and akathisia in chronic psychiatric inpatients. Psychopharmacol Bull. 1987; 23(1):215-7.
      View in: PubMed
    168. Asnis GM, Halbreich U, Ryan ND, Rabinowicz H, Puig-Antich J, Nelson B, Novacenko H, Friedman JH. The relationship of the dexamethasone suppression test (1 mg and 2 mg) to basal plasma cortisol levels in endogenous depression. Psychoneuroendocrinology. 1987; 12(4):295-301.
      View in: PubMed
    169. Buckler RA, Friedman JH. Maprotiline-induced ataxia. J Clin Psychopharmacol. 1986 Dec; 6(6):382-3.
      View in: PubMed
    170. De Amicis LA, Goldberg DC, LoPiccolo J, Friedman J, Davies L. Three-year follow-up of couples evaluated for sexual dysfunction. J Sex Marital Ther. 1984; 10(4):215-28.
      View in: PubMed
    171. Stewart DJ, Leavens M, Friedman J, Benjamin RS, Moore EC, Bodey GP, Valdivieso M, Burgess MA, Wiseman C, Loo TL. Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Res. 1980 Sep; 40(9):3163-6.
      View in: PubMed
    172. Friedman J, McCallum P, Meares R. Stimulus intensity control in depression: a study of the comparative effect of doxepin and amitriptyline on cortical evoked potentials. Aust N Z J Psychiatry. 1980 Jun; 14(2):115-9.
      View in: PubMed
    173. Horvath T, Friedman J, Meares R. Attention in hysteria: a study of Janet's hypothesis by means of habituation and arousal measures. Am J Psychiatry. 1980 Feb; 137(2):217-20.
      View in: PubMed
    174. Loo TL, Friedman J, Moore EC, Valdivieso M, Marti JR, Stewart D. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans. Cancer Res. 1980 Jan; 40(1):86-90.
      View in: PubMed
    175. Friedman J, Meares R. Cortical evoked potentials and severity of depression. Am J Psychiatry. 1979 Sep; 136(9):1218-20.
      View in: PubMed
    176. Friedman J, Meares R. The effect of placebo and tricyclic antidepressants on cortical evoked potentials in depressed patients. Biol Psychol. 1979 Jun; 8(4):291-302.
      View in: PubMed
    177. Coombs LC, Freedman R, Friedman J, Pratt WF. Premarital pregnancy and status before and after marriage. AJS. 1970 Mar; 75(5):800-20.
      View in: PubMed
    178. FRIEDMAN JH, HADER M, DUTCHEN W, BRESSLER DM. THE PROGNOSIS OF THE PSYCHONEUROSES IN YOUNGER ADULTS AS PREDICATED FROM A GERIATRIC MENTAL HYGIENE CLINIC. Am J Psychiatry. 1965 Apr; 121:1014-7.
      View in: PubMed
    179. WISOTSKY M, FRIEDMAN JH. PROBLEMS OF PSYCHOLOGIC TESTING WITH AGED PATIENTS IN A GERIATRIC MENTAL HYGIENE CLINIC. J Am Geriatr Soc. 1965 Mar; 13:243-7.
      View in: PubMed
    Friedman's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067